
|Videos|July 31, 2020
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
AAO 2025: A practice’s experience with connecting "the why," building community for techs
3
Ophthalmology over the decades: A catalyst of innovation in the 1970s
4
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
5